Search results for "MAb"
showing 10 items of 1716 documents
Development and validation of a liquid chromatography tandem mass spectrometry method for the analysis of beta-agonists in animal feed and drinking w…
2010
A reproducible, sensitive and selective multiresidue analytical method for seven beta-agonists: clenbuterol (CBT), clenpenterol (CPT), ractopamine (RTP), brombuterol (BBT), mabuterol (MBT), mapenterol (MPT), and hydroxymethylclenbuterol (HMCBT) was developed and validated by using liquid chromatography tandem mass spectrometry (LC-MS/MS) in feed and drinking water samples. The validation was achieved according to the criteria laid down in the Commission Decision 2002/657/EC, however it was necessary to use minimum required performance limits (MRPLs) proposed by the Community Reference Laboratories (CRLs) due to the lack of maximum residue limits (MRLs) for beta-agonists. By setting up these…
Abstract 2903: IMAB362, a novel first-in-class monoclonal antibody for treatment of pancreatic cancer
2014
Abstract Pancreatic ductal adenocarcinoma (PDAC), the most frequent subtype (>80%) of pancreatic cancer (PC) is characterized by a generally lethal progress within a short period of time after primary diagnosis. Despite high efforts, the treatment options are very limited and mainly of palliative nature. Therefore, we investigated whether IMAB362 might represent a potential treatment option in this patient population. IMAB362 is a highly potent and tumor-cell selective therapeutic antibody which is currently in clinical development in gastro-esophageal cancer (in phase II and IIb trials). IMAB362 is directed against the tight junction molecule CLDN18.2, a proliferation-promoting tran…
The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-l…
2012
TPS3637 Background: GA201 is a novel, dual-acting, humanized, glycoengineered IgG1 anti-EGFR monoclonal antibody, with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity in combination with signal inhibition. GA201 demonstrates significantly enhanced in vitro/vivo activity compared to cetuximab (cet) both as a single agent and in combination with irinotecan, in both KRAS mutant and BRAF mutant models and promising clinical activity in ph I and neo-adjuvant trials (Paz Ares et al, JCO 2011) including KRAS mutant mCRC. A randomized ph II program was launched: one study in NSCLC and GAIN-C in mCRC (NCT01326000), which is presented here. Methods: Main inclusion criteria are prog…
Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer
2007
Angiogenesis is the process by which new blood vessels are created from pre-existing vessels. It is essential for the growth and development of normal cells and tissues during embryonic and neonatal development and of tumour cells. Solid tumours rely on having an extensive network of blood vessels for growth and survival. The key mediator of angiogenesis, vascular endothelial growth factor-A (VEGF-A), is critical for the growth of tumours and their subsequent metastasis and is known to initiate angiogenesis. Bevacizumab is a humanized immunoglobulin G monoclonal antibody that binds to VEGF with high specificity, thereby blocking VEGF-mediated signalling pathways and thus angiogenesis. Clini…
A Hardware and Secure Pseudorandom Generator for Constrained Devices
2018
Hardware security for an Internet of Things or cyber physical system drives the need for ubiquitous cryptography to different sensing infrastructures in these fields. In particular, generating strong cryptographic keys on such resource-constrained device depends on a lightweight and cryptographically secure random number generator. In this research work, we have introduced a new hardware chaos-based pseudorandom number generator, which is mainly based on the deletion of an Hamilton cycle within the $N$ -cube (or on the vectorial negation), plus one single permutation. We have rigorously proven the chaotic behavior and cryptographically secure property of the whole proposal: the mid-term eff…
Highly Performant, Deep Neural Networks with sub-microsecond latency on FPGAs for Trigger Applications
2020
Artificial neural networks are becoming a standard tool for data analysis, but their potential remains yet to be widely used for hardware-level trigger applications. Nowadays, high-end FPGAs, often used in low-level hardware triggers, offer theoretically enough performance to include networks of considerable size. This makes it very promising and rewarding to optimize a neural network implementation for FPGAs in the trigger context. Here an optimized neural network implementation framework is presented, which typically reaches 90 to 100% computational efficiency, requires few extra FPGA resources for data flow and controlling, and allows latencies in the order of 10s to few 100s of nanoseco…
Efficient MLP Digital Implementation on FPGA
2005
The efficiency and the accuracy of a digital feed-forward neural networks must be optimized to obtain both high classification rate and minimum area on chip. In this paper an efficient MLP digital implementation. The key features of the hardware implementation are the virtual neuron based architecture and the use of the sinusoidal activation function for the hidden layer. The effectiveness of the proposed solutions has been evaluated developing different FPGA based neural prototypes for the High Energy Physics domain and the automatic Road Sign Recognition domain. The use of the sinusoidal activation function decreases hardware resource employment of about 32% when compared with the standar…
Properties of the Binary Neutron Star Merger GW170817
2019
On August 17, 2017, the Advanced LIGO and Advanced Virgo gravitational-wave detectors observed a low-mass compact binary inspiral. The initial sky localization of the source of the gravitational-wave signal, GW170817, allowed electromagnetic observatories to identify NGC 4993 as the host galaxy. In this work, we improve initial estimates of the binary's properties, including component masses, spins, and tidal parameters, using the known source location, improved modeling, and recalibrated Virgo data. We extend the range of gravitational-wave frequencies considered down to 23 Hz, compared to 30 Hz in the initial analysis. We also compare results inferred using several signal models, which ar…
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors
2022
Background: The combination of atezolizumab-bevacizumab has been proven to be superior to sorafenib for the treatment of unresectable hepatocellular carcinoma not amenable to locoregional treatments, be-coming the standard of care of systemic therapy.Aim: This study aimed at assessing real-world feasibility of atezolizumab-bevacizumab in patients treated with tyrosine-kinase inhibitors.Methods: Among 1447 patients treated with tyrosine-kinase inhibitors from January 2010 to December 2020, we assessed the percentage of those potentially eligible to atezolizumab-bevacizumab (according to IMbrave-150 trial criteria), and the overall survival of eligible and non-eligible patients.Results: 422 (…
Atopiska dermatīta smaguma pakāpes korelācija ar laboratorisko kritēriju un biežākas blaknes pacientiem ar bioloģisko terapiju
2021
Mērķis: Izpētīt un salīdzināt visbiežākās blaknes nemolizumab un lebrikizumab medikamentiem. Izpētīt laboratorisko rādītāju korelāciju ar AD smaguma pakāpi.Uzdevumi: Noteikt korelatīvas sakarības starp EASI, IgE, eozinofīliem leikocītiem, neitrofīliem leikocītiem, LDH. Salīdzināt nemolizumab un lebrikizumab medikamentu drošību. Materiāli un metodes: Retrospektīvs pētījums attiecībā uz 1.hipotēzi, izmantojot ambulatoro pacientu kartiņas. Pacienti ar vidēji smagu, smagu AD (kopā 59 cilvēki). Randomizēti, dubultakli, placebo-kontrolēti, multicentriski pētījumi, attiecība uz 2.hipotēzi. Kopējais pacientu skaits, ieskaitot pacientus, kuri saņēma bioloģisko terapiju - 424 (lebrikizumab) un 649 (n…